The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis.
The Ganoderma lucidum (Leyss. ex Fr.) Karst, an edible mushroom, has been utilized for centuries in East Asia to prevent or treat various diseases and to reduce the likelihood of cancer invasion and metastasis. The primary bioactive compounds are commonly considered to be polysaccharides and triterpenoids. Evidence that G. lucidum extract and its bioactive compounds may have a potential inhibitory effect on cancer invasion and metastasis is increasingly being reported in the scientific literature. This review assembles and summarizes past publications on the in vitro and in vivo effects of G. lucidum on cancer invasion and metastasis, and concludes that these effects occur through modulation of the phosphorylation of extracellular signal-regulated kinase (ERK1/2), phosphatidylinositol 3-kinase (PI 3-kinase) or Akt kinase (protein kinase B). Activation of these kinases subsequently inhibits the activity or expression of activator protein-1(AP-1) and nuclear factor-kappa B (NF-kappaB), resulting in the down-regulation of urokinase plaminogen activator (uPA), uPA receptor (uPAR), matrix metalloproteinase (MMP)-9, vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-beta1, interleukin (IL)-8, inducible nitric oxide (NO) and beta1-integrin as shown in various cell lines or animal models. G. lucidum may be an effective nutraceutical used in the prevention of cancer metastasis. To further elucidate the bioactive components present in G. lucidum and the anti-metastatic mechanisms underlying these compounds, more in vitro and in vivo tests as well as clinical trials are necessary.
Weng
Chia-Jui
CJ
Graduate Institute of Applied Science of Living, Tainan University of Technology, 529 Jhongjheng Road, Yongkang, Tainan, 71002, Taiwan.
Yen
Gow-Chin
GC
D000818:Animals; D006801:Humans; D066298:In Vitro Techniques; D009361:Neoplasm Invasiveness / Q000517:prevention & control*; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D010936:Plant Extracts / Q000494:pharmacology*; D020940:Reishi / Q000737:chemistry*
D010936:Plant Extracts
Bioorg Med Chem. 2002 Apr;10(4):1057-62
11836115
Anticancer Drugs. 2001 Jun;12(5):387-400
11395568
Arch Biochem Biophys. 2002 Dec 15;408(2):147-54
12464265
J Pharm Biomed Anal. 2008 Jul 15;47(3):469-77
18337046
Nat Rev Cancer. 2003 Jul;3(7):489-501
12835669
Nutr Cancer. 2005;53(1):11-7
16351502
J Ethnopharmacol. 2004 Jan;90(1):17-20
14698502
J Clin Oncol. 2000 Mar;18(5):1135-49
10694567
Curr Med Chem. 2000 Jul;7(7):715-29
10702635
Pharmacol Ther. 2003 Jul;99(1):113-32
12804702
Phytochemistry. 2006 Sep;67(18):1985-2001
16905165
Nature. 1993 Apr 29;362(6423):841-4
7683111
Cancer Lett. 2002 Aug 28;182(2):155-61
12048161
J Agric Food Chem. 2009 Jun 10;57(11):5049-57
19422227
Anticancer Res. 2002 Nov-Dec;22(6A):3309-18
12530080
J Nat Prod. 1991 Jul-Aug;54(4):998-1002
1791484
Beijing Da Xue Xue Bao Yi Xue Ban. 2007 Dec 18;39(6):653-6
18087562
Mini Rev Med Chem. 2008 Jun;8(7):677-88
18537723
Drug Discov Today. 2005 Dec;10(23-24):1584
16376814
Mol Nutr Food Res. 2007 Dec;51(12):1472-7
17979098
Int J Oncol. 2007 Apr;30(4):963-9
17332936
J Nat Prod. 2001 Aug;64(8):1121-2
11520245
Biochem Biophys Res Commun. 2002 Nov 8;298(4):603-12
12408995
Carcinogenesis. 2008 Jan;29(1):147-56
18024477
Int J Oncol. 2004 May;24(5):1093-9
15067330
Biochem Biophys Res Commun. 2005 Apr 29;330(1):46-52
15781230
Integr Cancer Ther. 2003 Dec;2(4):358-64
14713328
Perspect Biol Med. 2006 Spring;49(2):159-70
16702701
Chem Pharm Bull (Tokyo). 2004 Jun;52(6):688-95
15187388
Int J Mol Med. 2008 May;21(5):577-84
18425349
J Natl Cancer Inst. 1990 Jan 3;82(1):4-6
1688381
Int Immunopharmacol. 2007 Jun;7(6):864-70
17466920
Appl Microbiol Biotechnol. 2002 Nov;60(3):258-74
12436306
Acta Pharmacol Sin. 2004 Nov;25(11):1387-95
15525457
Nature. 1994 Feb 10;367(6463):576-9
8107827
Adv Cancer Res. 1990;54:159-211
1688681
Cancer Res. 1969 Mar;29(3):734-5
5813100
Cancer Chemother Pharmacol. 1999;43 Suppl:S42-51
10357558
Pharmacol Rep. 2010 Jan-Feb;62(1):150-63
20360625
Leuk Res. 2006 Jul;30(7):767-8
16458355
Cell. 1991 Jan 25;64(2):327-36
1703045
Matrix Biol. 1997 Mar;15(8-9):535-41
9138286
Int J Mol Med. 2006 Oct;18(4):657-64
16964420
J Pharmacol Sci. 2008 Oct;108(2):212-6
18946196
Biosci Biotechnol Biochem. 2008 Jun;72(6):1399-408
18540114
Acta Pharmacol Sin. 2004 Jun;25(6):833-8
15169641
J Nat Prod. 2004 Feb;67(2):300-10
14987072
FASEB J. 1999 May;13(8):781-92
10224222
Biosci Biotechnol Biochem. 2002 Dec;66(12):2626-31
12596858
Chem Biodivers. 2007 Feb;4(2):224-31
17311233
Chem Pharm Bull (Tokyo). 2002 Jun;50(6):837-40
12045343
Nat Rev Cancer. 2003 Dec;3(12):921-30
14737122
Exp Oncol. 2006 Mar;28(1):25-9
16614703
J Altern Complement Med. 2003 Aug;9(4):491-7
14499024
J Nat Prod. 1986 Jul-Aug;49(4):621-5
3783158
Immunopharmacology. 2000 May;47(2-3):63-83
10878284
Chem Rec. 2003;3(3):172-80
12900937
Chem Pharm Bull (Tokyo). 2000 Jul;48(7):1026-33
10923835
Adv Appl Microbiol. 1992;37:101-34
1642155
J Biol Chem. 2002 Feb 1;277(5):3150-7
11689575
J Pharmacol Sci. 2005 Oct;99(2):144-53
16230843